AbbVie Inc. (NYSE:ABBV) is a leading global biopharmaceutical company, competing with giants like Pfizer and Johnson & Johnson in delivering innovative treatments across immunology, oncology, and neuroscience. On February 4, 2026, Evercore ISI maintained its "Outperform" rating for AbbVie, with the stock priced at $218.69. However, the price target was adjusted from $232 to $228.
AbbVie's financial performance in the fourth quarter of 2025 was impressive, with sales reaching $16.62 billion, surpassing the consensus estimate of $16.42 billion. This represents a 10% increase on a reported basis and a 9.5% increase on an operational basis. The company's adjusted earnings per share rose by 25.5% to $2.71, exceeding the expected $2.65, as highlighted by Benzinga.
The growth was primarily driven by AbbVie's immunology portfolio, which generated global net revenues of $8.63 billion, reflecting an 18.3% increase. Skyrizi sales surged by 32.5% to $5.01 billion, and Rinvoq sales rose by 29.5% to $2.37 billion. However, Humira sales experienced a decline of 25.9%, totaling $1.25 billion.
In the neuroscience portfolio, sales climbed to $2.96 billion, a 17.9% increase. Vraylar contributed $1.02 billion, up 10.5%, while Botox Therapeutics saw growth with net revenues of $991 million, a 13.4% rise. The oncology portfolio faced a slight decline, generating $1.66 billion in sales, down 1.5%. Imbruvica's net revenues fell by 20.8% to $671 million, while Venclexta's revenues increased by 8.6% to $711 million.
AbbVie projects its 2026 profit to surpass Wall Street estimates, driven by robust sales of its newer immunology drugs, Skyrizi and Rinvoq. The current price of ABBV is $216.97, reflecting a decrease of 3.85% or $8.69. The stock has fluctuated between a low of $204.27 and a high of $220.85 today, with a market capitalization of approximately $383.47 billion.
